Arnaldo Isa, MD
Neurology · Maitland, FLNPI 1952390452
Payments from drug & device makers
Across 1,615 payments — averaging $331.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$149K
- Takeda Pharmaceuticals U.S.A., Inc.$140K
- Amneal Pharmaceuticals LLC$69K
- Teva Pharmaceuticals USA, Inc.$52K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$23K
- Janssen Research & Development, LLC$21K
- plus $80K from 54 others
What the payments were for
- Consulting fees$5,1515%
- Speaking & faculty fees$72,20069%
- Travel & lodging$1,3781%
- Food & beverage$26,04225%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$50,496
- AUBAGIO$17,137
- NURTEC ODT$10,722
- BioMonitor$140
- LEMTRADA$118
- Austedo XR$116
How this compares
$534,705 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 25 | $360,027 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 34 | $258,863 |
| NuplazidPimavanserin Tartrate | 45 | $219,150 |
| IngrezzaValbenazine Tosylate | 18 | $149,070 |
| RebifInterferon Beta-1a/Albumin | 11 | $135,050 |
| Kesimpta PenOfatumumab | 13 | $111,741 |
| AustedoDeutetrabenazine | 11 | $92,630 |
| Emgality PenGalcanezumab-Gnlm | 80 | $81,421 |
| CopaxoneGlatiramer Acetate | 13 | $72,779 |
| VimpatLacosamide | 25 | $66,204 |
| RytaryCarbidopa/Levodopa | 45 | $64,529 |
| Nurtec OdtRimegepant Sulfate | 31 | $59,832 |
| GocovriAmantadine Hcl | 22 | $59,570 |
| XcopriCenobamate | 14 | $52,319 |
| UbrelvyUbrogepant | 33 | $44,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $139,748 | $360,02725 claims |
| Grifols USA, LLCGamunex-C | $204 | $258,86334 claims |
| Acadia Pharmaceuticals IncNuplazid | $177 | $219,15045 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $52,366 | $165,40924 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,639 | $157,26330 claims |
| EMD Serono, Inc.Rebif | $877 | $135,05011 claims |
| UCB, Inc.Vimpat, Neupro | $1,206 | $105,60852 claims |
| AbbVieUbrelvy, Qulipta | $18,765 | $72,17551 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $69,329 | $71,519118 claims |
| PfizerNurtec Odt | $767 | $59,83231 claims |
| MDD US Operations, LLCGocovri | $406 | $59,57022 claims |
| SK Life Science, Inc.Xcopri | $351 | $52,31914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Maitland
- William HoneycuttMaitland$14.1M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.